New hope for rare breast cancer? trial of taletrectinib underway

NCT ID NCT06214793

Terminated Disease control Sponsor: Megan Kruse, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial is currently suspended and plans to enroll about 61 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Taletrectinib (a targeted oral drug)
What this could lead to: If it works, this could point toward a new treatment option for a rare, hard-to-treat form of breast cancer.
What could go wrong: The trial is small (61 people) and currently suspended, so results may be delayed or never come. It is also only for patients with a specific gene mutation, so it would not help most breast cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm invasive lobular breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States
Marone Cancer Center Cleveland Clinic Florida

Weston, Florida, 33331, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.